MASLD and peripheral arterial disease frequently coexist, share common risk factors, and may both benefit from emerging GLP-1 receptor agonist and multi-peptide agonist therapies.
Dual/triple peptide agonistsGLP-1 receptor agonists and emerging dual and triple peptide agonists under investigation for MASLD may simultaneously benefit peripheral arterial disease, offering a potential unified pharmacological approach.
What the researchers found
The literature review found that most clinical studies support an association between MASLD and PAD, particularly in the context of hepatic steatosis (fat accumulation in the liver). Evidence for associations with more advanced stages (steatohepatitis or fibrosis) is limited due to few biopsy-confirmed MASLD studies.
Management strategies for both conditions overlap significantly, centering on lifestyle modifications (diet, exercise, smoking cessation) and shared comorbidity management. Notably, GLP-1 receptor agonists and emerging dual and triple peptide agonists (investigated for MASLD) may provide cardiovascular benefits relevant to PAD. Established PAD medications like statins and aspirin may also benefit MASLD.
Why it matters
MASLD affects roughly 30% of the global population, and PAD affects over 200 million people worldwide. When they coexist, cardiovascular risk compounds significantly. The recognition that GLP-1 receptor agonists and newer multi-peptide agonists (like tirzepatide and retatrutide) could address both liver disease and vascular disease simultaneously represents a paradigm shift toward treating metabolic disease holistically rather than organ by organ.
How the study worked
The authors conducted a literature search of the PubMed database to identify clinical studies examining the association between MASLD and PAD. They critically appraised the evidence for this association and reviewed overlapping management strategies, with particular attention to pharmacological therapies that could benefit both conditions.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, so the literature search may not be comprehensive. Most evidence for the MASLD-PAD association comes from observational studies that cannot prove causation. Data on more advanced MASLD stages is scarce. No clinical trials have specifically evaluated medications for patients with both MASLD and PAD simultaneously. The potential benefits of GLP-1 agonists for PAD are largely extrapolated from cardiovascular outcome trials rather than PAD-specific studies.
How to read the evidence
This is a narrative review of observational and clinical studies, providing a moderate level of evidence for the MASLD-PAD association. The therapeutic recommendations are based on extrapolation from existing clinical trial data rather than trials specifically designed for patients with both conditions.
When this study was published
Published in 2026, this is a very current review reflecting the latest understanding of metabolic disease interconnections and the expanding therapeutic potential of peptide-based agonists.
The bigger picture
This review reflects the evolving understanding that metabolic diseases are interconnected systems rather than isolated conditions. GLP-1-based peptide therapies are increasingly recognized for benefits that extend across multiple organs — liver, heart, blood vessels, kidneys, and brain. The emergence of dual (GIP/GLP-1) and triple (GIP/GLP-1/glucagon) peptide agonists represents the cutting edge of metabolic pharmacology, potentially treating fatty liver, cardiovascular disease, and diabetes through a single medication.
Questions still open
- Will clinical trials specifically test GLP-1 receptor agonists in patients with both MASLD and PAD?
- Do dual and triple peptide agonists offer greater cardiovascular protection than single GLP-1 receptor agonists in patients with fatty liver disease?
- Could treating MASLD with peptide-based therapies directly reduce PAD progression, or do the benefits work only through shared risk factor management?
Common questions
How are fatty liver disease and peripheral artery disease connected?
Could GLP-1 drugs treat both conditions at once?
Read the original research
Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment Considerations.
Current vascular pharmacology
Citation
Polyzos, Stergios A; Orfanidou, Myrsini; Kountouras, Jannis; Goulas, Antonis. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment Considerations.. Current vascular pharmacology. https://doi.org/10.2174/0115701611414052251127074106